Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of pneumonia and sepsis risks between enzalutamide and abiraterone in with cancer
    Meeting Abstract

    Lee, A.; Chan, J.; Leung, C. H.; Liu, A.; Dee, E.; Ng, K.; Tse, G.; Leung, D.; Leung, C. F.
    European Respiratory Journal (2024)

    Fulltext@MSK | Save
  • Results from CA240-0007, a phase 1/2 multiple expansion cohort study of BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del)
    Meeting Abstract

    Rodon, J.; Jänne, P. A.; Leventakos, K.; George, B.; Henry, J. T.; Johnson, M. L.; Papadopoulos, K. P.; Batista, A. I.; Spira, C. P.; Zhao, Y.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • The role of regulatory T cells in thymic regeneration
    Meeting Abstract

    Lemarquis, A.; Kousa, A.; Argyropoulos, K.; Dudakov, J.; Dewolf, S.; van den Brink, M.
    European Journal of Immunology (2024)

    Fulltext@MSK | Save
  • Divergent roles for STAT4 in shaping differentiation of cytotoxic ILC1 and NK cells during gut inflammation
    Meeting Abstract

    Scarno, G.; Mazej, J.; Laffranchi, M.; Di Censo, C.; Mattiola, I.; Candelotti, A. M.; Pietropaolo, G.; Stabile, H.; Fionda, C.; Peruzzi, G.; more...
    European Journal of Immunology (2024)

    Fulltext@MSK | Save
  • Modeling-based assessment of exposure measurements after high-dose targeted (131)I-apamistamab: Results and analyses from the phase III SIERRA trial
    Meeting Abstract

    Pandit-Taskar, N.; Chen, L.; Serencsits, B.; Prasad, K.; Senglaub, T.; Zgaljardic, M.; Spross, J.; Desai, A.; Brodin, P.
    European Journal of Nuclear Medicine and Molecular Imaging (2024)

    Fulltext@MSK | Save
  • PD-L1 ligation enhances NK cell anti-tumor function by inducing a metabolic shift
    Meeting Abstract

    Srpan, K.; Lupo, K.; Hsu, K.
    European Journal of Immunology (2024)

    Fulltext@MSK | Save
  • Updated safety and efficacy from a phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Wolpin, B.; Hong, D.; Spira, A.; Starodub, A.; Park, W.; Sommerhalder, D.; Valerin, J.; Barve, M.; Punekar, S.; Pelster, M.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Tumor adaptation to PI3K inhibition and its stability increases as a function of time and is overcome by combined inhibiting Bcl2 family proteins
    Meeting Abstract

    Mukherjee, R.; Vanaja, K. G.; Sharma, M.; Solomon, H.; De Stanchina, E.; Chandarlapaty, S.; Rosen, N.
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (trial in progress)
    Meeting Abstract

    Baldini, C.; Patnaik, A.; Lakhani, N.; Call, J.; Galsky, M.; Garmezy, B.; Wei, A.; Carter, L.; Powles, T.; Siefker-Radtke, A.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)
    Meeting Abstract

    Tran, B.; Boni, A.; Hansen, A.; Boni, V.; Mantia, C.; Yu, E.; Weickhardt, A.; Robert, M.; Gupta, S.; Necchi, A.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save